血液检测MACK-3用于非侵入性诊断纤维化性非酒精性脂肪性肝炎的验证:一项纳入1924例患者的国际研究
本研究在来自亚洲、澳大利亚和欧洲10个中心的1924例经活检证实为非酒精性脂肪性肝病的患者中,验证血液检测MACK-3对纤维化性非酒精性脂肪性肝炎的诊断准确性。MACK-3的受试者工作特征曲线下面积为0.791(95%CI 0.768-0.814),在既往发表的阈值下敏感度为91%、特异度为85%,且不受年龄、性别、糖尿病或体重指数影响。结论认为MACK-3是改善非酒精性脂肪性肝炎治疗试验患者筛选的准确工具。
要点
- MACK-3诊断纤维化性非酒精性脂肪性肝炎的受试者工作特征曲线下面积为0.791(95%CI 0.768-0.814)。
- MACK-3阈值<0.135时敏感度为91%,>0.549时特异度为85%。
- MACK-3与FAST结果良好相关(Spearman相关系数0.781;P<.001),准确性相似。
核心结论
- 血液检测MACK-3是改善非酒精性脂肪性肝炎治疗试验患者筛选的准确工具。
研究设计与样本
- 国际多中心研究,纳入来自亚洲、澳大利亚和欧洲10个中心的1924例经活检证实为非酒精性脂肪性肝病的患者。
- 所有患者计算MACK-3血液检测,其中655例患者亚组另具备基于弹性成像的FAST评分。
- 纤维化性非酒精性脂肪性肝炎定义为肝活检存在非酒精性脂肪性肝炎且非酒精性脂肪性肝病活动度评分≥4、纤维化分期≥F2(NASH临床研究网络评分系统)。
主要发现
- MACK-3诊断纤维化性非酒精性脂肪性肝炎的受试者工作特征曲线下面积为0.791(95%CI 0.768-0.814)。
- 在既往发表的MACK-3阈值<0.135时敏感度为91%,在>0.549阈值时特异度为85%。
- MACK-3的受试者工作特征曲线下面积不受年龄、性别、糖尿病或体重指数影响。
- MACK-3与FAST结果良好相关(Spearman相关系数0.781;P<.001)。
- 除灰区患者比例高8%外,MACK-3提供的准确性与FAST相似;两种检测均将27%的患者纳入其排除区,特异度85%,假阳性率(筛选失败率)35%。
关键数值与推荐
- MACK-3阈值<0.135时敏感度为91%。
- MACK-3阈值>0.549时特异度为85%。
- MACK-3与FAST的Spearman相关系数为0.781(P<.001)。
- MACK-3和FAST均将27%的患者纳入排除区,特异度85%,假阳性率(筛选失败率)35%。
- MACK-3灰区患者比例较FAST高8%。
临床怎么用
- 原文结论认为MACK-3是改善非酒精性脂肪性肝炎治疗试验患者筛选的准确工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Drug development in nonalcoholic steatohepatitis (NASH) is hampered by a high screening failure rate that reaches 60% to 80% in therapeutic trials, mainly because of the absence of fibrotic NASH on baseline liver histology. MACK-3, a blood test including 3 biomarkers (aspartate aminotransferase, homeostasis model assessment, and cytokeratin 18), recently was developed for the noninvasive diagnosis of fibrotic NASH. We aimed to validate the diagnostic accuracy of this noninvasive test in an international multicenter study. METHODS: A total of 1924 patients with biopsy-proven nonalcoholic fatty liver disease from 10 centers in Asia, Australia, and Europe were included. The blood test MACK-3 was calculated for all patients. FibroScan-aspartate aminotransferase score (FAST), an elastography-based test for fibrotic NASH, also was available in a subset of 655 patients. Fibrotic NASH was defined as the presence of NASH on liver biopsy with a Nonalcoholic Fatty Liver Disease Activity Score of 4 or higher and fibrosis stage of F2 or higher according to the NASH Clinical Research Network scoring system. RESULTS: The area under the receiver operating characteristic of MACK-3 for fibrotic NASH was 0.791 (95% CI 0.768-0.814). Sensitivity at the previously published MACK-3 threshold of less than 0.135 was 91% and specificity at a greater than 0.549 threshold was 85%. The MACK-3 area under the receiver operating characteristic was not affected by age, sex, diabetes, or body mass index. MACK-3 and FAST results were well correlated (Spearman correlation coefficient, 0.781; P < .001). Except for an 8% higher rate of patients included in the grey zone, MACK-3 provided similar accuracy to that of FAST. Both tests included 27% of patients in their rule-in zone, with 85% specificity and 35% false positives (screen failure rate). CONCLUSIONS: The blood test MACK-3 is an accurate tool to improve patient selection in NASH therapeutic trials.
引用
- Canivet CM, Zheng MH, Qadri S, et al. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients. Clin Gastroenterol Hepatol. 2023. PMID: 37031715. doi:10.1016/j.cgh.2023.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。